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Identity 
Other names: 5DII; D2; SelY; TXDI2 




The Dio2 gene is composed of 3 exons comprising 
14656 bp of the genomic DNA. 
Transcription 
The length of transcribed mRNA is about 6,8 kb and 
generates three variants of mRNA. Transcript variant 1 
represents the longest transcript and encodes isoform a. 
Transcript variant 2 differs in the 5'UTR when 
compared to variant 1. Both variants 1 and 2 encode 
isoform a. Transcript variant 3 includes an alternate in-
frame exon in the coding region, compared to variant 1. 
Variant 3 encodes isoform b, which is longer than 
isoform a. 
Pseudogene 
No pseudogene have been described. 
Protein 
Description 
The protein encoded by this gene belongs to the 
iodothyronine deiodinase family. This enzyme activates 
thyroid hormone by converting the prohormone 
thyroxine (T4) by outer ring deiodination to bioactive 
3,3',5-triiodothyronine (T3). It is highly expressed in 
the thyroid, and may contribute significantly to the 
relative increase in thyroidal T3 production in patien s 
with Graves' disease and thyroid adenomas. This 
protein contains selenocysteine (Sec) residues encod d 
by the UGA codon, which often signals the end of 
process of translation. The 3'UTR of Sec-containing 
genes have a common stem-loop structure, the sec 
insertion sequence (SECIS), which is necessary for the 
recognition of UGA as a Sec codon rather than a stop
signal. Alternative splicing results in multiple transcript 
variants encoding different isoforms. Ubiquitination 
can also regulate proteins by transiently inactivating 
enzymatic function through conformational change in a
dimeric enzyme, which can be reversed upon 
deubiquitination (post-translational). 
  
Organization of the Dio2 gene: Yellow bars represent the coding region (exon) and red bars, the untranslated region. 
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Schematic representation of D2 peptide structure (not on scale). Isoform a (273 aa) and Isoform b (309 aa). In deep green 
transmembran domain (position 10-34). In yellow active site (position 133). In deep blue alternative sequence isoform b (position 74). 
 
Expression 
Ohba et al. (2001) identified 2 alternatively spliced 
DIO2 transcripts that include intronic sequences 
between the 2 invariant DIO2 exons. These splice 
variants showed tissue-specific expression in brain, 
thyroid, liver, thymus, anterior pituitary gland and 
brown adipose tissue. In mesothelioma cell lysates, 
Curcio et al. (2001) determined that endogenous DIO2 
gene had an apparent molecular mass of 31 kD. In 
normal tissues, D2 activity/mRNA ratio is variable, but 
the enzyme is expressed in rodents in the developing 
and adult testis, heart, muscle, thyroid, BAT, brain, 
pituitary, thymus, skin, spinal cord, placenta, liver and 
pancreas. In humans D2 is expressed in brain, BAT, 
heart, thyroid, muscle, placenta, skin and vascular 
smooth muscle cells. 
Localisation 
Immuno location of the protein in cells showed D2 as 
an endoplasmic reticulum resident protein. 
Function 
Type 2 deiodinase converts intracellular pro-hormone-
3,3',5,5'-tetraiodothyronine (T4) into the active thyroid 
hormone 3,3',5-triiodothyronine (T3) thereby 
regulating intracellular levels of active T3 in target 
tissues.  
Thermogenesis  
The expression of D2 is increased in response to cold 
stimulation in brown adipocytes isolated from mice. 
Dio2 activation in the brown adipose tissue (BAT) of 
human newborns and rodents is known to play a role in 
adaptive energy expenditure during cold exposure. 
Development 
D2 activity is present in human placenta through all 
pregnancy, and is highly expressed during the first 
trimester. The level of activity is low in the non-
pregnant uterus, but in pregnancy the level rises 
progressively to a maximum at gestation day 17 when 
it is increased threefold. 
Homology 
Several homologues of Dio2 have been identified in 
Pan troglodytes and Macaca mulatta (100%). The 




human Dio2 (97%). Human Dio2 homology with D3 is  
expressed in Sus scrofia, Equus caballus, Cricetus 
cricetus, Oryctolagus cuniculus, Pituophis deppei (92% 
similarity) and limited domains with human D3 and D1. 
Mutations 
Note 
No germinal or somatic mutations has been described. 
However, the polymorphism Thr92Ala in Dio2 gene is 
associated with increased risk of mental retardation, 
insulin resistance in type 2 diabetic patients, reduc  
glucose availability in obese women, symptomatic 




Although not completely understood, Dio2 gene 
expression and activity is altered in some tumors. It is
under-expressed in papillary thyroid carcinomas (PTC). 
In follicular tumors, D2 activity is similar or elevated 
when compared to non tumoral tissues, and augmented 
in follicular adenomas. D2 is also highly expressed in 
medullar thyroid carcinoma. A higher expression of the
Dio2 gene was also described in gliosarcoma, 
oligoastrocytoma, glioblastoma, oligodendroglioma 
and pituitary tumors. In contrast, meningioma does not 
express D2 activity. These differences might be related 
to the embrionary tumor origin. Mesothelioma 
expresses higher activity of D2, whereas osteosarcoma 
has diminished D2 activity. 
Insulin resistance 
Note 
Dio2 polymorphism Thr92Ala interacts with a 
polymorphism in PPAR gamma 2 gene and is 
associated with insulin resistance in diabetic patients. 
This Dio2 polymorphism is associated with a ~20% 
lower rate of glucose disposal in obese women than in 
non-obese women. Although the association between 
those two genes occurs in patients with insulin 
resistance, these results are contradictory in non 
diabetic population. 
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Hypothyroidism 
Note 
Disruption in mouse Dio2 gene is associated with 
alterations in T4/T3 balance with elevated TSH levels, 
which demonstrates that the Dio2 gene is of critical 




It is suggested that the Thr92Ala variant of the Dio2 
gene is associated or might be in linkage disequilibrium 
with a functional DIO2 polymorphism which involves 




A case control study in Chinese patients demonstrated 
that two allelic intronic SNPs (rs225010 (T/C) and 
rs225012 (A/G)) in the DIO2 gene could affect the 
amount of T3 available and in an iodine-deficient 
environment and partially determine on augmented risk 
of mental retardation. They found a positive association 
with mental retardation and the two intronic Dio2 
polymorphisms but not with Dio2 Thr92Ala alone and 
concluded that the genetic variation in Dio2 determine 
the risk of development of mental retardation that could 
be due to alterations in the local amount of T3 avail ble 
in the brain. 
Bone metabolism 
Note 
Dio2 is expressed in human and mouse osteoblast cell .
In patients with differentiated thyroid carcinoma, the 
Dio2 Thr92Ala polymorphism is associated with a 
decreased femoral neck bone mineral density and 
higher bone turnover independent of serum thyroid 
hormone levels. 
Cardiomyopathy and arterial 
hypertension 
Note 
Dio2 gene expression is also markedly up-regulated in 
hearts of mice that develops hypothyroidism or 
eccentric hypertrophy after myocardial infarction. The 
Dio2 polymorphism Thr92Ala is also associated with 
increased risk for the development of hypertension. 
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